Phase I DNA Immunotherapy Trial Initiated in Adults with Breast, Lung, and Pancreatic Cancer

Share this content:

the Cancer Therapy Advisor take:

High levels of hTERT (human telomerase reverse transcriptase) expression are found in 85% of human cancers, and is therefore a significant target for cancer treatment.

Therefore, Inovio Pharmaceuticals recently announced it has initiated a phase I trial of hTERT DNA immunotherapy alone or in combination with an interleukin-12 immune activator (INO-9012; also from Inovio), which will be conducted at the University of Pennsylvania's Abramson Cancer Center.

In a previous study that looked at the activity of the drug in monkeys, who have similar TERT to humans, strong immune responses were observed and showed the potential to destroy cancer cells.  The phase I trial is an open-label, dose-escalation study in patients with breast, lung, or pancreatic cancer who are at risk for relapse after surgery or chemotherapy/radiation.

The safety and tolerability of INO-1400 alone or in combination with INO-9012 will be evaluated, with a secondary objective to determine immune responses and evaluate immunotherapy-induced changes. Lung, breast, and pancreatic cancers were selected for this study because they have the first, third, and fourth highest mortality rates, and patients with these diseases often relapse despite surgery and adjuvant therapy.

The hope is that this drug will be yet another weapon in the armament of immunotherapies aimed at empowering the patient’s own immune system to fight their cancer.

Phase I Trial of hTERT DNA Immunotherapy Initiated in Adults with Breast, Lung, and Pancreatic Cance
High levels of hTERT expression are found in 85% of human cancers.
Inovio Pharmaceuticals, Inc. announced it has initiated a phase I trial of its hTERT DNA immunotherapy (INO-1400) alone or in combination with Inovio's IL-12 immune activator (INO-9012) in adults with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other cancer treatments.
READ FULL ARTICLE From News Medical

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs